Andrew Guggenhime, PRESIDENT AND CFO at Vaxcyte, Inc. (PCVX), sold 16,000 shares at $83.64 ($1.3M) on 2025-02-18, disclosed to the SEC on 2025-02-19.
Scheduled sale ($1.3M) by PRESIDENT AND CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $83.64 | 6,182 | $517K | 38.5% |
| 2 | $83.64 | 6,182 | $517K | 38.5% |
| 3 | $84.58 | 1,818 | $154K | 11.5% |
| 4 | $84.58 | 1,818 | $154K | 11.5% |
| Total | $83.85 avg | 16,000 | $1.3M | 100% |
| Filing → |
| PCVX | SELL | 2026-06-18 | $530K | — | Filing → |
| PCVX | SELL | 2025-01-22 | $1.4M | — | Filing → |
| PCVX | SELL | 2024-12-19 | $1.4M | — | Filing → |